## Please fax all pages of completed form to your team at 888.302.1028.

To reach your team, call toll-free 844.516.3319.

You can now monitor shipments and chat online if you have questions. Go to MyAccredoPatients.com to log in or get started.

Prescription & Enrollment Form

Multiple Sclerosis—Interferons



## Four simple steps to submit your referral.

1 Patient Information	tion	Please provand prescri	ride copies of front and back of all medical ption insurance cards.
New patient			
Patient's first name		Last name	Middle initial
Preferred patient first name		Preferred patier	nt last name
Sex at birth: Male Female G	ender identity	Pronouns	Last 4 digits of SSN
Date of birthStr	eet address		Apt #
City		State	Zip
Home phone	Cell phone	Email	address
Parent/guardian (if applicable)			
Home phone	Cell phone	Email	address
Alternate caregiver/contact			
Home phone	Cell phone	Email	address
OK to leave message with alternate	te caregiver/contact		
Patient's primary language: Engli	sh Other If other, ple	ase specify	
			eded
Office/clinic/institution name			
Prescriber info: Prescriber's first nan	ne	Last	name
Prescriber's title		If NP or PA, under directi	on of Dr
Office phone	Fax	NPI #	License #
Office contact and title		Office	contact email
Office street address			Suite #
City		State	Zip
Infusion location: Patient's home	Prescriber's office Inf	usion site If infusion site, cor	mplete information below dotted line:
Infusion info: Infusion site name		Clinic/hospital a	ffiliation
Site street address			Suite #
City		State	Zip
Infusion site contact	Phone	Fax	Email
3 Clinical Informa	tion		
•			(+/-) Date

Patient's first name	Last name	Middle initial	Date of birth
Prescriber's first name	Last name	Phone	

## 4

## **Prescribing Information**

Medication	Strength/Formulation	Directions	Quantity/Refills
Avonex® (interferon beta-1a)	30mcg prefilled syringe (PFS) 30mcg Avonex Pen (single dose)	Inject 30mcg intramuscularly once a week. Dose Titration:  • Week 1: Inject 7.5mcg intramuscularly weekly  • Week 2: Inject 15mcg intramuscularly weekly  • Week 3: Inject 22.5mcg intramuscularly weekly  • Week 4+: Inject 30mcg intramuscularly weekly	4-week supply (1 kit) 12-week supply (3 kits) Refills
Betaseron® (interferon beta-1b)	0.3mg vial	Inject 0.25mg (1mL) subcutaneously every other day.  Dose Titration:  Weeks 1–2: Inject 0.0625mg/0.25mL subcutaneously every other day  Weeks 3–4: Inject 0.125mg/0.50mL subcutaneously every other day  Weeks 5–6: Inject 0.1875mg/0.75mL subcutaneously every other day  Weeks 7+: Inject 0.25mg/1mL subcutaneously every other day  Other	28-day supply (1 kit/14 vials) 84-day supply (3 kits/42 vials) Other
Extavia® (interferon beta-1b)	0.3mg vial	Inject 0.25mg (1mL) subcutaneously every other day. Dose Titration:  • Weeks 1–2: Inject 0.0625mg/0.25mL subcutaneously every other day  • Weeks 3–4: Inject 0.125mg/0.50mL subcutaneously every other day  • Weeks 5–6: Inject 0.1875mg/0.75mL subcutaneously every other day  • Weeks 7+: Inject 0.25mg/1mL subcutaneously every other day	30-day supply (1 kit) 90-day supply (3 kits) Refills
Plegridy® (peginterferon beta-1a) (Subcutaneous injection)	0.5mL Autoinjector pen PFS	Titration:  Day 1 inject 63mcg under the skin,  Day 15 inject 94mcg under the skin,  Day 29 inject 125mcg under the skin and repeat every 14 days.  Inject 125mcg under the skin every 14 days.  Other	Patient is currently receiving a: 1-month supply 3-month supply  Dispense: 1-month supply 3-month supply Other
Plegridy® (peginterferon beta-1a) (Intramuscular injection)	0.5mL PFS	Titration:  Day 1 inject 63mcg into the muscle,  Day 15 inject 94mcg into the muscle,  Day 29 inject 125mcg into the muscle and repeat every 14 days.  Note: see manufacturer form for titration clips prescription for intramuscular injection.  Inject 125mcg into the muscle every 14 days.  Other	Refills
Other			30-day supply 90-day supply Other Refills

**Ancillary Supplies:** (Prescriber to strike through if not required) Dispense ancillary supplies such as needles, syringes, sterile water, etc. and home medical equipment necessary to administer the therapy as needed. Send quantity sufficient for medication days supply

If shipped to physician's office, physician accepts on behalf of patient for administration in office.

Prescriber's signature required	(sign below)	(Physician attests this is his/her legal signature. NO STAMPS

SIGN					
SIGN HERE	Date	Dispense as written	Date	Substitution allowed	

Prescription	Q.	Enrollment	Form.	Multiple	Sclarocic_	Interference
Prescribtion	Ōκ	Enrollment	FORIII:	wullible	Scierosis-	·mterierons

Fax completed form to 888.302.1028.

Patient's first name	Last name	Middle initial	Date of birth
Prescriber's first name	Last name	Phone	
<b>A</b> Prescribing Information			

Medication	Strength/Formulation	Directions	Quantity/Refills
Rebif® (interferon beta-1a)	Titration Pack (six 8.8mcg and 22mcg PFS) 22mcg PFS 44mcg PFS Titration Pack Rebidose® (six 8.8mcg prefilled autoinjectors and six 22mcg prefilled autoinjectors) Rebidose® 22mcg prefilled autoinjector Rebidose® 44mcg prefilled autoinjector	Inject 8.8mcg subcutaneously three times a week weeks 1–2, 22mcg subcutaneously three times a week weeks 3–4, and 44mcg subcutaneously three times a week weeks 5+.  Inject 44mcg subcutaneously three times a week.  Other	4-week supply (1 kit) 12-week supply (3 kits) Other Refills
Other			30-day supply 90-day supply Other

Ancillary Supplies: (Prescriber to strike through if not required) Dispense ancillary supplies such as needles, syringes, sterile water, etc. and home medical equipment necessary to administer the therapy as needed. Send quantity sufficient for medication days supply

If shipped to physician's office, physician accepts on behalf of patient for administration in office.

Prescriber's signature required (sign below) (Physician attests this is his/her legal signature. NO STAMPS)

SIGN	
HERE	

Date	Dispense as written	Date	Substitution allowed

The prescriber is to comply with his/her state-specific prescription requirements such as e-prescribing, state-specific prescription form, fax language, etc. Non-compliance with state-specific requirements could result in outreach to the prescriber.

